Nautilus Biotechnology (NASDAQ:NAUT) Releases Quarterly Earnings Results

Nautilus Biotechnology (NASDAQ:NAUT) issued its quarterly earnings results on Monday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03, FiscalAI reports. The business had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.25 million.

Nautilus Biotechnology Stock Performance

NASDAQ NAUT opened at $1.66 on Tuesday. Nautilus Biotechnology has a 52-week low of $0.62 and a 52-week high of $4.31. The company has a fifty day moving average of $2.13 and a 200-day moving average of $2.45. The company has a market capitalization of $210.95 million, a P/E ratio of -3.61 and a beta of 0.80.

Insider Buying and Selling

In related news, major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $2.35, for a total value of $11,750,000.00. Following the transaction, the insider owned 971,885 shares of the company’s stock, valued at $2,283,929.75. This represents a 83.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 41.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Nautilus Biotechnology

Several hedge funds have recently added to or reduced their stakes in the company. Marshall Wace LLP purchased a new position in shares of Nautilus Biotechnology in the 4th quarter worth about $228,000. Jane Street Group LLC increased its position in shares of Nautilus Biotechnology by 304.1% during the 2nd quarter. Jane Street Group LLC now owns 290,369 shares of the company’s stock valued at $210,000 after purchasing an additional 218,512 shares during the last quarter. OMERS ADMINISTRATION Corp purchased a new position in shares of Nautilus Biotechnology during the 4th quarter valued at about $204,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of Nautilus Biotechnology during the 1st quarter valued at about $194,000. Finally, Squarepoint Ops LLC lifted its position in Nautilus Biotechnology by 29.5% in the 3rd quarter. Squarepoint Ops LLC now owns 131,827 shares of the company’s stock worth $111,000 after buying an additional 30,005 shares during the last quarter. Institutional investors own 50.71% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $4.00.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.